

Aravax appoints Dr Brett Haumann to Board of Directors

11 May 2022 | News

Dr Brett Haumann is a GlaxoSmithKline (GSK) veteran



Australia's Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, announced the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors.

Dr Haumann is a pharma veteran with leadership experience spanning preclinical discovery, clinical discovery and development, project leadership, alliance management, business development and both executive and non-executive Board of Director roles. He currently serves as the Chief Medical Officer of ReViral, a UK-based company developing novel antiviral therapeutics to target Respiratory Syncytial Virus (RSV). Prior to this, Dr Haumann spent seven years as Chief Medical Officer and Senior Vice President of Development at Theravance Biopharma where he developed a broad portfolio of novel assets in multiple therapeutic areas, including Yupelri for the treatment of COPD.

Before Theravance, Dr Haumann spent more than 15 years in senior development roles at GlaxoSmithKline (GSK), including as Vice President of Clinical Development, where he served as the global Medicines Development Leader to lead the successful development and approval of Relvar/Breo for the treatment of asthma and COPD.

He has also served as a non-executive director on a number of private and public boards in Europe and the US, including most recently as the Head of the R&D Committee on the Board of Aimune Therapeutics which launched Palforzia®, the first registered therapy for the treatment of peanut allergy in the United States.